FrancophonIA/ELRC3.0 huggingface dataset:
English: If you missed a dose of Zoledronic Acid Hospira Contact your doctor or hospital as soon as possible to re-schedule your appointment.
Slovenian: Če ste izpustili odmerek zdravila Zoledronska kislina Hospira Čimprej pokličite zdravnika ali v bolnišnico, da se dogovorite za naslednji obisk.
English: It is given as a single 15-minute intravenous infusion in a separate infusion line.
Slovenian: Daje se v obliki ene same 15-minutne intravenske infuzije z ločenim infuzijskim sistemom.
English: To prepare reduced doses for patients with baseline CLcr ≤ 60 ml/min, refer to Table 1 below.
Slovenian: Za pripravo zmanjšanih odmerkov za bolnike z izhodiščnim CLcr ≤ 60 ml/min glejte spodnjo preglednico 1.
English: It is currently unclear whether zoledronic acid causes this irregular heart rhythm but you should report it to your doctor if you experience such symptoms after you have received zoledronic acid.
Slovenian: Zaenkrat ni jasno, ali to nepravilno bitje srca povzroča zoledronska kislina, kljub temu pa morate zdravniku sporočiti, če pri vas pride do takih simptomov po tem, ko ste prejeli zoledronsko kislino,
English: If you have pre-existing hypocalcaemia, it must be corrected before initiating the first dose of Zoledronic Acid Hospira.
Slovenian: Če imate hipokalciemijo, jo je treba odpraviti preden prejmete prvi odmerek zdravila Zoledronska kislina Hospira.
English: * Doses have been calculated assuming target AUC of 0.66 (mg•hr/l) (CLcr = 75 ml/min).
Slovenian: * Odmerke so izračunali s predvidenim ciljnim AUC 0,66 (mg•hr/l) (CLcr = 75 ml/min).
English: − Conjunctivitis.
Slovenian: − konjunktivitis,
English: The long duration of action of zoledronic acid is attributable to its high binding affinity for the active site of farnesyl pyrophosphate (FPP) synthase and its strong binding affinity to bone mineral.
Slovenian: Dolgotrajno delovanje zoledronske kisline je mogoče pripisati veliki vezavni afiniteti do aktivnega mesta na farnezil pirofosfat-sintazi in močni vezavni afiniteti do kostnih mineralov.
English: In the intravenous bolus studies, the doses that were well-tolerated decreased with increasing study duration: 0.2 and 0.02 mg/kg daily was well tolerated for 4 weeks in rats and dogs, respectively but only 0.01 mg/kg and 0.005 mg/kg in rats and dogs, respectively, when given for 52 weeks.
Slovenian: V študijah z intravenskimi bolusi so se odmerki, ki so jih živali dobro prenašale, zmanjševali s podaljševanjem študije: odmerek 0,2 oziroma 0,02 mg/kg na dan so podgane in psi dobro prenašali 4 tedne, medtem ko so tako podgane kot psi 52 tednov dolgo dajanje zdravila dobro prenašali le v odmerku 0,01 mg/kg oziroma 0,005 mg/kg:
English: Proportion of patients with SREs (%)
Slovenian: 4 mg placebo delež bolnikov s SRE (%)
English: The hydration status of patients must be assessed prior to and following administration of zoledronic acid to ensure that they are adequately hydrated.
Slovenian: Status hidracije bolnikov mora zdravnik oceniti pred in po dajanju zoledronske kisline, da se prepriča, da so ustrezno hidrirani.
English: Follow carefully all instructions given to you by your doctor or nurse.
Slovenian: Natančno upoštevajte navodila, ki vam jih je dal vaš zdravnik ali medicinska sestra.
English: Factors that may increase the potential for deterioration in renal function include dehydration, pre-existing renal impairment, multiple cycles of zoledronic acid or other bisphosphonates, as well as concomitant use of nephrotoxic medicinal products or using a shorter infusion time than currently recommended.
Slovenian: Med dejavniki, ki lahko povečajo možnost poslabšanja delovanja ledvic, so dehidracija, predhodna ledvična okvara, večkratni ciklusi zdravljenja z zoledronsko kislino ali drugimi difosfonati, kot tudi sočasna uporaba nefrotoksičnih zdravil ali čas infundiranja, ki je krajši od priporočenega.
English: ** Based on post-marketing reports.
Slovenian: ** na podlagi postmarketinških poročil; pogostnostni ni mogoče oceniti iz razpoložljivih podatkov.
English: In clinical trials 69 patients who relapsed or were refractory to initial treatment (zoledronic acid 4 mg, 8 mg or pamidronate 90 mg) were retreated with 8 mg zoledronic acid.
Slovenian: V kliničnih preskušanjih je bilo 69 bolnikov, pri katerih se je bolezen ponovno pojavila ali pri katerih ni bilo odziva na začetno zdravljenje (zoledronska kislina 4 mg, 8 mg ali pamidronat 90 mg), ponovno zdravljenih z 8 mg zoledronske kisline.
English: Very Rare (may affect up to 1 in 10,000 people) Talk to your doctor if you have ear pain, discharge from the ear, and/or an ear infection.
Slovenian: Zelo redki (lahko se pojavijo pri največ 1 od 10.000 bolnikov) V primeru bolečine v ušesu, izcedka iz ušesa in/ali okužbe ušesa se posvetujte z zdravnikom.
English: What Zoledronic Acid Hospira is and what it is used for What you need to know before you are given Zoledronic Acid Hospira How Zoledronic Acid Hospira is given Possible side effects
Slovenian: Kaj je zdravilo Zoledronska kislina Hospira in za kaj ga uporabljamo Kaj morate vedeti, preden vam bodo dali zdravilo Zoledronska kislina Hospira Kako se daje zdravilo Zoledronska kislina Hospira Možni neželeni učinki
English: Clear and colourless solution.
Slovenian: bistra in brezbarvna raztopina
English: In patients with normal renal function, defined as CLcr > 60 ml/min, zoledronic acid 4 mg/100 ml solution for infusion must not be further diluted.
Slovenian: Pri bolnikih z normalnim delovanjem ledvic, kar je opredeljeno kot CLcr > 60 ml/min, zoledronske kisline 4 mg/100 ml raztopina za infundiranje ni treba dodatno razredčiti.
English: The European Medicines Agency has waived the obligation to submit the results of studies with the reference medicinal product containing zoledronic acid in all subsets of the paediatric population in Paget's disease of the bone (see section 4.2 for information on paediatric use).
Slovenian: Evropska agencija za zdravila je odstopila od zahteve za predložitev rezultatov študij z zoledronsko kislino za vse podskupine pediatrične populacije s Pagetovo boleznijo kosti (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
English: Patients should have their serum creatinine levels assessed prior to each dose of zoledronic acid.
Slovenian: Bolnikom je treba pred vsakim odmerkom zoledronske kisline določiti raven serumskega kreatinina.
English: Zoledronic acid 4 mg reduced the risk of SREs by 41% in a multiple event analysis (risk ratio=0.59, p=0.019) compared with placebo.
Slovenian: Pri analizi večkratnih dogodkov se je pokazalo, da je zoledronska kislina 4 mg zmanjšala tveganje za SRE za 41 % (razmerje tveganj = 0,59; p = 0,019) v primerjavi s placebom.
English: Zoledronic acid was studied in male and female patients aged above 30 years with primarily mild to moderate Paget's disease of the bone (median serum alkaline phosphatase level 2.6-3.0 times the upper limit of the age-specific normal reference range at the time of study entry) confirmed by radiographic evidence.
Slovenian: Zoledronsko kislino so proučevali pri bolnicah in bolnikih, starejših od 30 let, z rentgenološko potrjeno primarno blago do zmerno Pagetovo boleznijo kosti (mediana aktivnost alkalne fosfataze v serumu je bila 2,6 do 3-krat večja od zgornje meje starostno specifičnega normalnega referenčnega območja v času vstopa v študijo).
English: After first opening: From a microbiological point of view, the product should be used immediately.
Slovenian: Po prvem odprtju: z mikrobiološkega vidika je treba zdravilo uporabiti takoj.
English: − if you have or have had pain, swelling or numbness of the jaw, a feeling of heaviness in the jaw or loosening of a tooth.
Slovenian: − če imate ali ste v preteklosti imeli bolečino, oteklino ali odrevenelost v čeljusti, če čutite težo v čeljusti ali se vam maje zob.
English: Zoledronic acid must only be prescribed and administered to patients by healthcare professionals experienced in the administration of intravenous bisphosphonates.
Slovenian: Zoledronsko kislino smejo predpisovati in dajati bolnikom samo zdravstveni delavci, ki imajo izkušnje z uporabo intravenskih difosfonatov.
English: The active substance in Zoledronic Acid Hospira is zoledronic acid, which belongs to a group of substances called bisphosphonates.
Slovenian: Učinkovina v zdravilu Zoledronska kislina Hospira je zoledronska kislina, ki sodi v skupino snovi, ki se imenujejo difosfonati.
English: Dystocia was observed at the lowest dose (0.01 mg/kg body weight) tested in rats.
Slovenian: Distocijo so ugotovili pri najnižjem odmerku (0,01 mg/kg telesne mase), ki so ga preskušali pri podganah.
English: Longer-term repeat administration at cumulative exposures sufficiently exceeding the maximum intended human exposure produced toxicological effects in other organs, including the gastrointestinal tract and liver, and at the site of intravenous administration.
Slovenian: Dolgotrajno večkratno dajanje pri kumulativnih izpostavljenostih, ki močno presegajo največjo nameravano izpostavljenost pri človeku, je povzročilo toksikološke učinke v drugih organih, vključno z gastrointestinalnim traktom in jetri, in na mestu intravenske aplikacije.
English: Abdominal pain Musculoskeletal and connective tissue disorders Common:
Slovenian: bolečine v trebuhu Bolezni mišično-skeletnega sistema in vezivnega tkiva Pogosti:
English: How to store Zoledronic Acid Hospira Contents of the pack and other information
Slovenian: Shranjevanje zdravila Zoledronska kislina Hospira Vsebina pakiranja in dodatne informacije
English: Common C-reactive protein increased Uncommon Blood calcium decreased Observed in patients taking concomitant glucocorticosteroids.
Slovenian: Preiskave pogosti zvišana vrednost C-reaktivnega proteina občasni znižana vrednost kalcija v krvi pri bolnikih, ki so sočasno jemali glukokortikoide.
English: − Since no data are available on the compatibility of Zoledronic Acid Hospira with other intravenously administered substances, Zoledronic Acid Hospira must not be mixed with other medicinal products/substances and should always be given through a separate infusion line.
Slovenian: − Ker o združljivosti zdravila Zoledronska kislina Hospira z drugimi intravensko dajanimi snovmi ni na voljo nikakršnih podatkov, zdravila Zoledronska kislina Hospira ne smete mešati z drugimi zdravili ali snovmi in ga moramo vedno dajati po ločenem infuzijskem sistemu.
English: Factors that may increase the potential for deterioration in renal function include dehydration, pre-existing renal impairment, multiple cycles of zoledronic acid and other bisphosphonates as well as use of other nephrotoxic medicinal products.
Slovenian: Med dejavniki, ki utegnejo zvečati možnost poslabšanja ledvične funkcije so dehidracija, že obstoječa ledvična okvara, več ciklov zdravljenja z zoledronsko kislino in drugimi difosfonati, pa tudi uporaba drugih nefrotoksičnih zdravil.
English: The use of Zoledronic Acid Hospira in patients with severe renal impairment (creatinine clearance < 35 ml/min) is contraindicated due to an increased risk of renal failure in this population.
Slovenian: Uporaba zdravila Zoledronska kislina Hospira pri bolnikih s hudo okvaro ledvic (očistek kreatinina < 35 ml/min) je kontraindicirana zaradi povečanega tveganja za odpoved pri tej populaciji.
English: p-value Median time to SRE (days)
Slovenian: mediana časa do SRE (dnevi)
English: Patients with TIH and evidence of deterioration in renal function should be appropriately evaluated with consideration given as to whether the potential benefit of treatment with zoledronic acid outweighs the possible risk.
Slovenian: Bolnike s tumorsko povzročeno hiperkalciemijo (TIH) in z znaki poslabšanja ledvične funkcije, moramo ustrezno ovrednotiti in pri tem pretehtati, ali možna korist zdravljenja z zoledronsko kislino odtehta morebitno tveganje.
English: For patients with normal renal function (defined as CLcr > 60 ml/min), zoledronic acid 4 mg/100 ml solution for infusion may be administered directly without any further preparation.
Slovenian: Bolniki z normalnim delovanjem ledvic (opredeljeno kot CLcr > 60 ml/min), lahko zoledronsko kislino 4 mg/100 ml raztopino za infundiranje prejmejo neposredno brez nadaljnje priprave.
English: − Low level of magnesium and potassium in the blood.
Slovenian: − nizki koncentraciji magnezija in kalija v krvi.
English: It is important for you to drink at least 2 glasses of fluid (such as water), within a few hours before receiving Zoledronic Acid Hospira, as directed by your healthcare provider.
Slovenian: Pomembno je, da v nekaj urah pred prejemom zdravila Zoledronska kislina Hospira popijete vsaj 2 kozarca tekočine (na primer vode), kakor vam naroči zdravstveni delavec, s katerim sodelujete.
English: The use of zoledronic acid in patients with severe renal impairment (creatinine clearance < 35 ml/min) is contraindicated due to an increased risk of renal failure in this population.
Slovenian: Uporaba zoledronske kisline je pri bolnikih s hudo okvaro ledvic (očistek kreatinina < 35 ml/min) kontraindicirana zaradi povečanega tveganja za odpoved ledvic pri tej populaciji.
English: Zoledronic acid should only be resumed when serum creatinine returns to within 10% of baseline.
Slovenian: Zdravljenje z zoledronsko kislino se sme spet začeti šele, ko se serumski kreatinin vrne na vrednost, ki ni za več kot 10% večja od izhodiščne.
English: It is currently unclear whether zoledronic acid causes this irregular heart rhythm but you should report it to your doctor if you experience such symptoms after you have received Zoledronic Acid Hospira.
Slovenian: Zaenkrat ni jasno, ali to nepravilno bitje srca povzroča zdravilo Zoledronska kislina Hospira, kljub temu pa morate zdravniku sporočiti, če pri vas pride do takih simptomov po prejemu zdravila Zoledronska kislina Hospira.
English: Zoledronic acid treatment should be resumed at the same dose as that given prior to treatment interruption.
Slovenian: Zdravljenje z zoledronsko kislino je treba spet začeti z enakim odmerkom, kot ga je bolnik prejemal pred prekinitvijo zdravljenja.
English: Solution for infusion 4 mg/100 ml
Slovenian: raztopina za infundiranje 4 mg/100 ml
English: In a large clinical trial, local reactions at the infusion site, such as redness, swelling and/or pain, were reported (0.7%) following the administration of zoledronic acid.
Slovenian: V obsežnem kliničnem preskušanju so po odmerjanju zoledronske kisline poročali o lokalnih reakcijah, kot so rdečina, oteklina in/ali bolečina (0,7 %).
English: For atrial fibrillation serious adverse events the pooled incidences were 1.3% for zoledronic acid and 0.8% for placebo.
Slovenian: Združeni incidenci atrijske fibrilacije, ki so jo opredelili kot resen neželen učinek, sta bili 1,3 % pri zoledronski kislini in 0,8 % pri placebu.
English: Your doctor can recommend a mild pain reliever such as ibuprofen or paracetamol to reduce these side effects.
Slovenian: Za ublažitev teh neželenih učinkov vam zdravnik lahko svetuje blago zdravilo proti bolečinam, kot sta ibuprofen ali paracetamol.
English: − if you are allergic (hypersensitive) to zoledronic acid, another bisphosphonate (the group of substances to which zoledronic acid belongs), or any of the other ingredients of Zoledronic Acid Hospira.
Slovenian: − če ste alergični (preobčutljivi) na zoledronsko kislino, drug difosfonat (skupina snovi, ki ji pripada zoledronska kislina) ali katerokoli sestavino zdravila Zoledronska kislina Hospira
English: Concentrate for solution for infusion 4 mg/5 ml
Slovenian: koncentrat za raztopino za infundiranje 4 mg/5 ml
English: − Sleepiness
Slovenian: − zaspanost,
English: Interstitial lung disease (inflammation of the tissue around the air sacks of the lungs)
Slovenian: − intersticijska bolezen pljuč (vnetje tkiva okoli pljučnih mešičkov),
English: In view of the potential impact of zoledronic acid on renal function, the lack of clinical safety data in patients with severe renal impairment (in clinical trials defined as serum creatinine 400 µmol/l or 4.5 mg/dl for patients with TIH and 265 µmol/l or 3.0 mg/dl for patients with cancer and bone metastases, respectively) at baseline and only limited pharmacokinetic data in patients with severe renal impairment at baseline (creatinine clearance < 30 ml/min), the use of zoledronic acid is not recommended in patients with severe renal impairment.
Slovenian: Glede na možni vpliv zoledronske kisline na delovanje ledvic ob pomanjkanju kliničnih podatkov o varnosti pri bolnikih s hudo izhodiščno okvaro ledvic (v kliničnih preskušanjih opredeljeno s serumskim kreatininom ≥ 400 μmol/l ali ≥ 4,5 mg/dl pri bolnikih s tumorsko povzročeno hiperkalciemijo - TIH - oziroma s serumskim kreatininom ≥ 265 μmol/l ali ≥ 3,0 mg/dl pri bolnikih z rakom in zasevki v kosteh) in glede na samo omejene farmakokinetične podatke pri bolnikih s hudo izhodiščno ledvično okvaro (očistek kreatinina < 30 ml/min), uporabe zoledronske kisline pri bolnikih s težko ledvično okvaro ne priporočamo.
English: Based on the review of both clinical trial and post-marketing cases, there is sufficient evidence to support an association between zoledronic acid therapy, the reported event of hypocalcaemia, and the secondary development of cardiac arrhythmia.
Slovenian: Po pregledu podatkov kliničnih preskušanj in primerov, ki so jih opažali po prihodu zdravila na trg, je na voljo dovolj dokazov, ki povezujejo zdravljenje z zoledronsko kislino, opisane primere hipokalciemije in posledičen razvoj aritmije.
English: After initiation of the zoledronic acid infusion, plasma concentrations of the active substance increased rapidly, achieving their peak at the end of the infusion period, followed by a rapid decline to < 10% of peak after 4 hours and < 1% of peak after 24 hours, with a subsequent prolonged period of very low concentrations not exceeding 0.1% of peak levels.
Slovenian: Po začetku infundiranja zoledronske kisline so se koncentracije učinkovine v plazmi hitro zvišale, dosegle ob koncu infundiranja vrh, ki mu je sledilo hitro znižanje na < 10 % najvišje dosežene vrednosti po 4 urah in na < 1 % najvišje dosežene vrednosti po 24 urah, čemur je sledilo dolgotrajno obdobje zelo nizkih koncentracij, ki niso presegle 0,1 % najvišje vrednosti.
English: There was a transient increase in serum creatinine observed within 10 days in 1.8% of zoledronic acid-treated patients versus 0.8% of placebo-treated patients.
Slovenian: V prvih 10 dneh po odmerjanju je prišlo do prehodnega zvišanja vrednosti kreatinina v serumu pri 1,8 % bolnikov v skupini z zoledronsko kislino v primerjavi z 0,8 % bolnikov v skupini s placebom.
English: Only limited pharmacokinetic data are available in patients with severe renal insufficiency (creatinine clearance < 30 ml/min).
Slovenian: Pri bolnikih s hudo ledvično insuficienco (očistek kreatinina < 30 ml/min) so na voljo le omejeni farmakokinetični podatki).
English: − To prepare an infusion solution containing 4 mg zoledronic acid, further dilute the Zoledronic Acid Hospira concentrate (5.0 ml) with 100 ml of calcium-free or other divalent cation-free infusion solution.
Slovenian: − Infuzijsko raztopino, ki vsebuje 4 mg zoledronske kisline, pripravite tako, da dodatno razredčite koncentrat zdravila Zoledronska kislina Hospira (5,0 ml) s 100 ml infuzijske raztopine, ki ne vsebuje kalcija ali drugih dvovalentnih kationov.
English: In patients with Paget's disease, it is strongly advised that adequate supplemental calcium corresponding to at least 500 mg elemental calcium twice daily is ensured for at least 10 days following Zoledronic Acid Hospira administration (see section 4.4).
Slovenian: Pri bolnikih s Pagetovo boleznijo je zelo priporočeno zadostno dodajanje kalcija, ki ustreza vsaj 500 mg elementarnega kalcija, in sicer dvakrat na dan vsaj 10 dni po uporabi zdravila Zoledronska kislina Hospira (glejte poglavje 4.4).
English: The inter- and intra-subject variation for plasma clearance of zoledronic acid was shown to be 36% and 34%, respectively.
Slovenian: Pokazali so, da je variabilnost plazemskega očistka zoledronske kisline med preskušanci 36 %, pri posameznem preskušancu pa 34 %.
English: What Zoledronic Acid Hospira is and what it is used for
Slovenian: Kaj je zdravilo Zoledronska kislina Hospira in za kaj ga uporabljamo
English: From the bone tissue it is released very slowly back into the systemic circulation and eliminated via the kidney.
Slovenian: Iz kostnega tkiva se zelo počasi sprošča nazaj v sistemski krvni obtok in se izloča iz telesa skozi ledvice.
English: Of the 153 zoledronic acid-treated patients and 115 risedronate-treated patients who entered an extended observation study, after a median duration of follow-up of 3.8 years from time of dosing, the proportion of patients ending the Extended Observation Period due to the need for re-treatment (clinical judgment) was higher for risedronate (48 patients, or 41.7%) compared with zoledronic acid (11 patients, or 7.2%).
Slovenian: zdravljenih z risedronatom, ki so bili vključeni v študijo podaljšanega opazovanja, je bil po povprečnem trajanju spremljanja 3,8 let od časa odmerjanja delež bolnikov, ki so zaključili svoje sodelovanje v podaljšanem obdobju opazovanja, ker so potrebovali ponovno zdravljenje (po presoji zdravnika), večji v skupini bolnikov, ki so prejemali risedronat, (48 bolnikov oziroma 41,7 %) kot v skupini bolnikov, ki so prejemali zoledronsko kislino (11 bolnikov oziroma 7,2 %).
English: - Zoledronic Acid Hospira 4 mg/100 ml solution for infusion can be used immediately without further preparation for patients with normal renal function.
Slovenian: − Zdravilo Zoledronska kislina Hospira 4 mg/100 ml raztopina za infundiranje je mogoče uporabiti takoj, brez nadaljnje priprave, pri bolnikih z normalnim delovanjem ledvic.
English: As with other bisphosphonates, the retention time of zoledronic acid in bones is very long.
Slovenian: Zoledronska kislina se, tako kot drugi difosfonati, zelo dolgo zadržuje v kosteh.
English: Table 6: Adverse reactions observed in paediatric patients with severe osteogenesis imperfecta Nervous system disorders
Slovenian: Preglednica 6: Neželeni učinki, ki so jih opažali pri pediatričnih bolnikih s hudo obliko osteogenesis imperfecta
English: Adjusted dose (mg zoledronic acid) *
Slovenian: Prilagojeni odmerek (mg zoledronske kisline) *
English: Other products containing zoledronic acid as active substance are available for osteoporosis indications and treatment of Paget´s disease of the bone.
Slovenian: Na voljo so tudi druga zdravila, ki vsebujejo učinkovino zoledronska kislina, in se uporabljajo za zdravljenje osteoporoze in Pagetove bolezni kosti.
English: Zoledronic Acid Hospira should be given as a single intravenous infusion in no less than 15 minutes.
Slovenian: Zdravilo Zoledronska kislina Hospira je treba dati v obliki ene intravenske infuzije, ki traja najmanj 15 minut.
English: Following initiation of therapy, serum creatinine should be measured prior to each dose of Zoledronic Acid Hospira and treatment should be withheld if renal function has deteriorated.
Slovenian: Po uvedbi terapije je treba izmeriti serumski kreatinin pred vsakim odmerkom zdravila Zoledronska kislina Hospira, terapijo pa je treba prekiniti, če se je ledvična funkcija poslabšala.
English: Cardiac disorders Uncommon: Hypertension, hypotension, atrial fibrillation, hypotension leading to syncope or circulatory collapse
Slovenian: hipertenzija, hipotenzija, atrijska fibrilacija, hipotenzija, ki povzroči sinkopo ali cirkulatorni kolaps
English: Table 3: Efficacy results (prostate cancer patients receiving hormonal therapy)
Slovenian: Preglednica 3: Rezultati učinkovitosti (bolniki z rakom prostate, ki so prejemali hormonsko zdravljenje)
English: − Unusual fracture of the thigh bone particularly in patients on long-term treatment for osteoporosis may occur rarely.
Slovenian: − redko se lahko pojavijo neobičajni zlomi stegnenice, še posebno pri bolnikih, ki so na dolgotrajnem zdravljenju osteoporoze.
English: Table 7: Adverse reactions observed in paediatric patients with severe osteogenesis imperfecta Nervous system disorders
Slovenian: Preglednica 7: Neželeni učinki, ki so jih opažali pri pediatričnih bolnikih s hudo obliko osteogenesis imperfecta